Akorn gets FDA warning letter related to New Jersey plant
Akorn Inc said on Tuesday the U.S. Food and Drug Administration has raised certain issues related to its Somerset, New Jersey manufacturing facility, sending the generic drugmaker's shares down nearly 13% premarket.
from Reuters: Health News https://reut.rs/2NcP8k7
http://bit.ly/2zwRqiM